We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Updated EMA Biosimilar Guidance Seeks Side-by-Side Quality Analysis
Updated EMA Biosimilar Guidance Seeks Side-by-Side Quality Analysis
June 7, 2012
Biosimilars’ molecular characteristics should mirror those of the reference biologic as closely as possible, while the performance and consistency of the biosimilars’ manufacturing process should stand on its own, the European Medicines Agency (EMA) says in an updated guideline. Includes the full text of EMA Guideline on Biosimilar Quality Comparisons.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor